Dupixent and Narrowband UVB for Atopic Dermatitis

StatusRecruiting
PhasePhase 4
Started

Record status This record was last updated March 15, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 1, 2024 to Dec 1, 2024
    • Study completion date: Mar 1, 2024 to Dec 15, 2024
    • Start date changed from estimate of Apr 1, 2022 to Apr 19, 2022
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Trial Details
NCT Number NCT05285839
Lead Sponsor Psoriasis Treatment Center of Central New Jersey
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov